Narodny Onkologicky Ustav

Narodny Onkologicky Ustav is conducting trials that explore new treatment options for prostate cancer, breast cancer, and other solid malignancies, aiming to improve survival and quality of life.

• Pre‑operative chemotherapy for high‑risk retroperitoneal sarcoma
• Combination of XL092 with immunotherapy for non‑clear cell renal cell carcinoma
• Androgen deprivation therapy plus darolutamide for metastatic prostate cancer
• Novel oral degrader ARV‑471 versus standard endocrine therapy in advanced breast cancer

The research emphasizes personalized approaches and integrates surgical and systemic strategies to advance care for patients across Bratislava and beyond.

Clinical studies at the site focus on innovative therapies for blood cancers such as follicular lymphoma and diffuse large B‑cell lymphoma, seeking to extend remission periods and reduce disease burden.

• CAR‑T cell therapy tisagenlecleucel compared with standard care for relapsed follicular lymphoma
• Epcoritamab combined with R‑CHOP versus R‑CHOP alone for newly diagnosed diffuse large B‑cell lymphoma

These trials highlight the institution’s commitment to bringing cutting‑edge immunotherapies to patients in Central Europe.

A dedicated trial evaluates rapid reversal agents for patients on factor Xa inhibitors, aiming to safely manage bleeding risk during urgent procedures.

• Andexanet alfa versus usual care for intra‑operative hemostasis in patients requiring urgent surgery

By addressing critical bleeding scenarios, the study supports safer surgical outcomes for individuals on modern anticoagulant therapy.